AbbVie: RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval

 

• RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA)
• RINVOQ is the first and only JAK inhibitor approved for both active ankylosing spondylitis (AS) and nr-axSpA^1-3
• In a clinical study, RINVOQ delivered rapid and meaningful disease control based on patients achieving ASAS40 vs. placebo, as well as significant improvement in signs and symptoms of nr-axSpA at week 14^1,2

https://www.biospace.com/article/releases/rinvoq-upadacitinib-receives-its-sixth-u-s-fda-approval/